Beating AbbVie’s TNF blocker Humira in a head-to-head trial has become a rite of passage for new interleukin-targeting drugs in the immunology market, but Novartis’ Cosentyx has just fallen ...

It’s two years since Novartis got its Cosentyx IL-17 drug approved for the spinal disease ankylosing spondylitis, and the Swiss pharma company has new data that it hopes will allow it to compete ...

Cosentyx (secukinumab) may be safe to use while pregnant or breastfeeding. Before starting treatment, you and your doctor can discuss the risks and benefits of Cosentyx treatment during pregnancy ...